NCT03753074 (ATTENTION) is a Phase 4 clinical trial of Tenofovir Alafenamide in Chronic Hepatitis b, sponsored by Young-Suk Lim.

Who is sponsoring NCT03753074?

NCT03753074 is sponsored by Young-Suk Lim.

What drugs are being tested in NCT03753074?

Interventions in NCT03753074: Tenofovir Alafenamide.

What condition does NCT03753074 study?

NCT03753074 studies Chronic Hepatitis b.

Is NCT03753074 still recruiting?

NCT03753074 is currently active, enrolled. Last updated 17 December 2024.

Last reviewed 2024-12-17 · How we verify

NCT03753074: ATTENTION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Active, enrolled Phase 4 Last updated 17 December 2024

What this trial tests

Phase 4 trial testing Tenofovir Alafenamide in Chronic Hepatitis b in 780 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 February 2019

Primary endpoint
31 December 2031

31 December 2031

Quick facts

Lead sponsor	Young-Suk Lim
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	780
Start date	18 February 2019
Primary completion	31 December 2031
Estimated completion	31 December 2031
Sites	10 locations across South Korea

Drugs / interventions tested

Tenofovir Alafenamide (TENOFOVIR ALAFENAMIDE) — full drug profile →

Conditions studied

Chronic Hepatitis b — all drugs for Chronic Hepatitis b →

Sponsor

Young-Suk Lim

Who can join

Adults 40 to 80, any sex, with Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment with Tenofovir Alafenamide(TAF) in Chronic Hepatitis B (CHB) patients classified as beyond treatment indication of current international guidelines (e.g. aged more than 40 years old and 4 ≤ log HBV-DNA IU/mL \< 8) is expected to bring improvement in long-term clinical outcomes. This expected result may expand the treatment indications in patients with CHB based on age and HBV-DNA in contrast to current international guidelines of CHB.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.
Lin CL, Kao JH. · · 2023 · cited 63× · PMID 36788759 · DOI 10.3350/cmh.2022.0342
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lim YS, Yu ML, Choi J, Chen CY, et al · · 2025 · cited 15× · PMID 39914435 · DOI 10.1016/s2468-1253(24)00431-x
The assessment of efficient representation of drug features using deep learning for drug repositioning.
Moridi M, Ghadirinia M, Sharifi-Zarchi A, Zare-Mirakabad F. · · 2019 · cited 8× · PMID 31726977 · DOI 10.1186/s12859-019-3165-y
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise.
Hur MH, Lee JH. · · 2023 · cited 2× · PMID 36907572 · DOI 10.3350/cmh.2023.0079

Verify or expand the search:

Other trials of Tenofovir Alafenamide

Trials testing the same drug.

NCT05467553 — A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection · Phase 2 · unknown
NCT05275023 — An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death P · Phase 2 · completed
NCT04891770 — Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of · Phase 2 · completed
NCT04674423 — The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Eleva · Phase 4 · unknown
NCT03887702 — Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therap · Phase 3 · terminated

Other recruiting trials for Chronic Hepatitis b

Currently open trials in the same condition.

NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
NCT06989788 — A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, · Phase 1 · active not recruiting
NCT06885710 — HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients · Phase 1 · recruiting
NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
NCT06638320 — Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection · active not recruiting

Other Young-Suk Lim trials

Trials by the same sponsor.

NCT03241641 — Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03753074 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Young-Suk Lim
Last refreshed: 17 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03753074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing